Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176933
Title: Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Author: Gonzalez Cao, Maria
Puertolas, Teresa
Riveiro, Mar
Muñoz Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer Palter, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera Álvarez, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet i Sala, Bonaventura
Martinez Picado, Javier
Cerezuela, Pablo
Soria, Ainara
Marquez, Ivan
Mandala, Mario
Berrocal, Alfonso
Spanish Melanoma Group (GEM).
Keywords: Melanoma
Immunoteràpia
Càncer
Melanoma
Immunotheraphy
Cancer
Issue Date: Mar-2021
Publisher: BMJ Publishing Group
Abstract: Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.
Note: Reproducció del document publicat a: https://doi.org/10.1136/jitc-2020-001664
It is part of: Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 3, p. e001664
URI: http://hdl.handle.net/2445/176933
Related resource: https://doi.org/10.1136/jitc-2020-001664
ISSN: 2051-1426
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
711684.pdf2.36 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons